Amicus Therapeutics — Q1 2022 Earnings Presentation
25 slides from Amicus Therapeutics's earnings presentation, May 9, 2022
Slide 1: 1Q22 Financial Results Conference Call & Webcast
1Q22 Financial Results Conference Call & Webcast May 9, 2022 At the Forefront of Therapies for Rare Diseases
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and
Slide 3: A Rare Company
3 A Rare Company Patient-Dedicated, Rare Disease Biotechnology Company with Sustained Double-Digit Revenue Growth, a Global Commercial Infrastructure, and Late-stage Development Capabilities AT-GAA a Two-Component Therapy Under Global Regulatory Reviews for Pompe Disease GLOBAL COMMERCIAL ORGANIZATI
Slide 4: 2022 Strategic Priorities to Drive Value
2022 Strategic Priorities to Drive Value 1 2 3 4 5 Double-digit Galafold growth (15-20%) with revenue of $350M to $365M at CER1 Secure FDA approval and positive CHMP opinion for AT-GAA Initiate successful, rapid launch in U.S. for AT-GAA Advance best-in-class next-generation genetic medicines and ca
Slide 5: Positioned for Significant Value Growth
5 Positioned for Significant Value Growth Focused on Execution and Driving Sustainable Double-Digit Revenue Growth on Path to Profitability Continue to bring Galafold® to as many patients as possible, sustain double-digit revenue growth Successful launch of AT-GAA for people living with Pompe diseas
Slide 6: Galafold (migalastat) Continued Growth
6 Galafold® (migalastat) Continued Growth... … building a leadership position in the treatment of Fabry disease
Slide 7: Galafold Success (as of March 31, 2022)
7 Galafold Success (as of March 31, 2022) Building on Galafold’s Success and Leveraging Leadership Position to Drive Continued Growth Galafold is indicated for adults with a confirmed diagnosis of Fabry Disease and an amenable variant. The most common adverse reactions reported with Galafold (≥10%)
Slide 8: Galafold Quarterly Trends
8 Galafold Quarterly Trends Q1 Reported Revenue Growth of +18.5% to $79M - Operational Growth of +23.5% at CER $71M $66M $77M $79M $82M $79M 4Q20 1Q21 2Q21 3Q21 4Q21 1Q22 Quarterly Galafold Reported Sales .. Global mix of switch (~55%) and previously untreated patients (~45%) .. Compliance and adher
Slide 9: Galafold Success and FY22 Revenue Guidance
9 Galafold Success and FY22 Revenue Guidance Galafold Momentum on Track to Achieve Full-Year 2022 Revenue Guidance at CER FY16 FY17 FY18 FY19 FY20 FY21 FY22 $5.0M Q1 $78.7M FY22 Rev. Guidance $350M-$365M at CER1 $36.9M $91.2M $182.2M $260.9M $305.5M 12022 Galafold revenue guidance utilizes the avera
Slide 10: Galafold Growth Opportunity
10 Penetration of the diagnosed untreated population Increase in newborn screening and diagnostic initiatives Strong intellectual property rights, including COM protection through 2038 Continued penetration into existing markets Expansion into new geographies Broadening of labels Galafold Growth Opp
Slide 11: Galafold Initiatives
11 Galafold Initiatives Building the Body of the Evidence around Galafold Broadening Labels: Adolescents and Additional Variants Publications and Medical Presentations Ongoing and Planned Phase IV Studies Over 500 Patients Enrolled in a Global Registry Strengthening our IP Portfolio
Slide 12: AT-GAA (cipaglucosidase alfa + miglustat)
12 AT-GAA (cipaglucosidase alfa + miglustat) … potential to establish a new standard of care for people living with Pompe disease
Slide 13: Pompe Disease Overview
13 Deficiency of GAA leading to lysosomal glycogen accumulation and cellular dysfunction Age of onset ranges from infancy to adulthood Symptoms include muscle weakness, respiratory failure, and cardiomyopathy Respiratory and cardiac failure are leading causes of morbidity and mortality Estimated inc
Slide 14: Phase 3 PROPEL Study Results Overall Population
14 Phase 3 PROPEL Study Results Overall Population (n=122*) Primary and First Key Secondary Endpoint Showed Greater Improvement with AT-GAA vs. alglucosidase alfa in the Overall Population of ERT-Naïve and ERT-Experienced Patients 6MWD=6-minute walk distance;; FVC=forced vital capacity; SE=standard
Slide 15: Phase 3 PROPEL Study Results ERT-Experienced Population
15 Phase 3 PROPEL Study Results ERT-Experienced Population (n=95) Results in the Large Pre-specified Subgroup of ERT-Experienced Patients with High Clinical Unmet Need Showed Meaningful Improvement for Both 6MWD and FVC 6MWD (m): Change from baseline (n=65, n=30) FVC (% predicted): Change from basel
Slide 16: Long-Term Data from Phase 1/2 Clinical Study (ATB200-02)
16 Long-Term Data from Phase 1/2 Clinical Study (ATB200-02) Persistent and Durable Improvements in Motor and Respiratory Function and Reductions in Biomarkers of Muscle Damage and Disease Substrate Observed in Patients out to 36 Months NOTE: * One patient in the ERT-naïve cohort experienced a large
Slide 17: AT-GAA: Key Takeaways
17 AT-GAA: Key Takeaways .. Regulatory status update: – U.S. PDUFA date mid 20221 – CHMP opinion late 2022 – Planning for additional regulatory submissions .. Multiple expanded access mechanisms in place, including in the U.K., Germany, France, Japan, and others .. 150+ people living with Pompe dise
Slide 18: Launch Preparations
18 Launch Preparations Experienced and Passionate Rare Disease Medical and Commercial Organization Poised for Second Successful Launch Key Strengths Commitment to patient access Clear focus on launch Identification of key Pompe disease treatment centers Development of educational materials Planning
Slide 19: Financial & Operational Strategy
19 Financial & Operational Strategy … maintaining a strong financial outlook
Slide 20: Revenue Performance
20 Revenue Performance Q1 Revenue Growth of +18.5% to $79M resulting from Strong Operational Growth of +23.5% at CER Offset by Negative FX impact of -5.0% $66.4M $78.7M -5.0% +23.5% 1Q21 Operational Growth FX Impact 1Q22 Year-over-Year Sales Growth .. Significant currency exposure as 69% of Galafold
Slide 21: 1Q2022 Select Financial Results
21 1Q2022 Select Financial Results 1Q22 OpEX Increase Reflects Manufacturing Costs to Support AT-GAA Launch and Non-Recurring Expenses Related to the Reprioritization of the Gene Therapy Portfolio Mar. 31, 2022 (in thousands, except per share data) Mar. 31, 2021 Product Revenue $78,715 $66,402 Cost
Slide 22: Financial Outlook and Path to Profitability
Financial Outlook and Path to Profitability Clear Strategy to Build our Business, Advance our Portfolio, and Achieve Profitability 22 Sustain Galafold Revenue Growth Deliver on Financial Goals Secure Approvals of AT-GAA $79M 1Q2022 revenue, +24% YoY Operational Growth 2022 Galafold revenue guidance
Slide 23: Thank You
A ba AMICUS Thank You
Slide 24: Appendix
° A WCcus AM endix p Ap
Slide 25: Reconciliation of Non-GAAP Financial Measures
Appendix Amicus Therapeutics, Inc. Reconciliation of Non-GAAP Financial Measures Total operating expenses - as reported GAAP Research and development: Share-based compensation Selling, general and administrative: Share-based compensation Loss on impairment of assets Changes in fair value of continge